Thiopurine effectiveness in patients with Crohn's disease: A study of genetic and clinical predictive factors

Inflammatory Bowel Diseases

Volumn 19, Issue 8, 2013, Pages 1639-1644

  Koifman, Eduard ^a   Karban, Amir ^a,b   Mazor, Yoav ^a   Chermesh, Irit ^a,b   Waterman, Matti ^a,b   Almog, Ronit ^c   Ben Horin, Shomron ^d   Eliakim, Rami ^d   Krivoy, Norberto ^b,e   Efrati, Edna ^b,e   Chowers, Yehuda ^a,b  

^a Rambam Health Care Campus ^*  (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c UNIVERSITY OF HAIFA   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e Clinical Pharmacology Institute   (Israel)

Author keywords

Polymorphisms; Predictive factors; RAC1; Thiopurine effectiveness

Indexed keywords

CASPASE 3; CASPASE 9; FAS LIGAND; MERCAPTOPURINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CROHN DISEASE; DRUG EFFICACY; FEMALE; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84884564480     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31828828d3     Document Type: Article

References (22)

1. Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;21:CD000067.
2. Dubinsky MC. Azathiorine, 6-MP in IBD: pharmacology, efficacy and safety. Clin Gastroenterol Hepatol. 2004;2:731-743.
3. Derijks LJ, Gilissen LP, Hooymans PM, et al. Thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:715-729.
4. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
5. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut. 2001;49:665-670.
6. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine-a long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-987.
7. Muise AM, Walters T, Xu W, et al. Single nucleotide polymorphisms that increase expression of the guanosine triphosphatase RAC1 are associated with ulcerative colitis. Gastroenterology. 2011;141:633-641.
8. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-1145.
9. Ben-Horin S, Goldstein I, Fudim E, et al. Early preservation of effector functions followed by eventual T-cell memory depletion: a model for delayed onset of the effect of thiopurines. Gut. 2009 58:396-403.
10. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
11. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther. 2001;15:1699-1708.
12. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of IBD: a 30 year review. Gut. 2002;50:485-489.
13. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
14. Bourgine J, Garat A, Allorge D. Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response? Pharmacogenet Genomics. 2011;21:313-324.
15. Hlavaty T, Pierik M, Henckaerts L. Polymorphisms in apoptosis genes predict response to infliximab in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther. 2005;22:613-626.
16. Ramaswamy M, Dumont C, Cruz AC, et al. Cutting edge: Rac GTPases sensitize activated T cells to die via Fas. J Immunol. 2007;179:6384-6388.
17. Pinto AL, Chebli LA, Ribeiro MS, et al. Azathioprine therapy in steroiddependent patients with Crohn disease: results of a 10-year longitudinal follow-up study. Med Sci Monit. 2009;15:PI19-PI26.
18. Bardhan KD, Simmonds N, Royston C, et al. A United Kingdom inflammatory bowel disease database: making the effort worthwhile. J Crohns Colitis. 2010;4:405-412.
19. Thia K, Li M, Ling KL. Azathioprine is effective in corticosteroid dependent Asian IBD patients. Inflamm Bowel Dis. 2011;17:809-815.
20. Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther. 2007;26: 217-225.
21. Costantino G, Federica Furfaro F, Alessandra Belvedere A, et al. Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up. J Crohns Colitis. 2012;6:588-596.
22. Vavricka SR, Rogler G, Fistula treatment: the unresolved challenge. Dig Dis. 2010;28:556-564.